Bristol-Myers Squibb (BMY) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company focuses on areas such as oncology, immunology, cardiovascular disease, and fibrosis. Its portfolio includes well-known products such as Opdivo, Eliquis, and Revlimid, which are pivotal in treating various cancers and other critical health conditions.
As a large-cap company, Bristol-Myers Squibb holds a significant position in the pharmaceutical industry, competing with other major players like Pfizer, Merck, and Johnson & Johnson. The company has maintained a strong market presence through strategic acquisitions and partnerships, enhancing its research and development capabilities while expanding its therapeutic offerings.
Bristol-Myers Squibb is recognized as a value stock with a history of paying dividends, making it attractive to income-focused investors. The company has recently shifted its strategic direction towards enhancing its pipeline of innovative therapies, particularly in immuno-oncology and cell therapy, to address unmet medical needs and drive future growth.